Bal Pharma Limited (BALPHARMA) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Bal Pharma Limited ₹77.48, price ₹108, upside -28.1%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bal Pharma Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹60.42 – ₹149.20 · fair‑value band ₹40.46 – ₹100.72 · the ₹107.71 price screens above the ₹77.48 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Bal Pharma in your weekly email
Every Wednesday you see whether Bal Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs.
Show more
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
Stock analysis
Bal Pharma Limited (BALPHARMA) currently trades at ₹107.71, while our model-based Fair Value estimate is ₹77.48, implying the stock looks roughly 39.0% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹86.83 per share, and 5 of the 16 models we run sit above the ₹107.71 price.
Bear case: the Dividend Discount group reads lowest at ₹17.40, and 11 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹40.46 (bear) to ₹100.72 (bull), the price of ₹107.71 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Bal Pharma Limited reported revenue of ₹3.1B in FY2026 versus ₹2.8B in FY2022, a compound +2.6%/yr. Reported net income was ₹62.8M in FY2026, compounding +2.9%/yr from FY2022.
Key figures
Market cap ₹1.7B (≈ $17.9M) · P/E ratio 27.3 · P/S ratio 0.55 · EPS (TTM) ₹3.95 · Dividend yield 1.1% · Net margin 2.0% · Return on equity 7.9% · Return on assets (EBIT) 5.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 6% below its 52-week high and 78% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −28%, BALPHARMA screens richer than that median.
Fair Value models
Bear ₹40.46Fair Value ₹77.48Bull ₹100.72
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹1.36 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2021 (pandemic). Over 10 years: +4.6% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.3%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2.3% vs 10.9%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 7%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 619 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside−28.1% · Below median
Profitability
Return on equity (TTM)7.9% · Above median
Return on assets3.7% · Above median
Net margin (TTM)2.0% · Below median
Operating margin (TTM)8.9% · Below median
Growth and dividend
Revenue growth2.7% · Below median
Dividend yield (TTM)1.1% · Below median
Balance sheet
Debt / equity0.39× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)27.3× · Pricier than median
P/B2.08× · Pricier than median
P/S (TTM)0.55× · Cheapest 25%
EV/EBITDA6.1× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)14· sector 18
PAST (return on equity)32· sector 26
HEALTH (low debt)81· sector 96
DIVIDEND (yield)22· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Bal Pharma Limited (BALPHARMA) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹77.48 versus a price of ₹107.71, about −28% upside (overvalued).
What is the fair value of BALPHARMA?
Our model-based fair value for Bal Pharma Limited is ₹77.48 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹107.71.
What is the quality score of BALPHARMA?
Bal Pharma Limited has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bal Pharma Limited (BALPHARMA)?
Our model-based price target is the fair value of ₹77.48 (as of Sep 27, 2026) from 16 valuation models. Cautious scenario ₹40.46, optimistic scenario ₹100.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Bal Pharma Limited stock forecast for 2026?
Our models put fair value at ₹77.48, about −28% upside versus a price of ₹107.71 (overvalued). Cautious scenario ₹40.46, optimistic scenario ₹100.72. The calculation is refreshed regularly with new filings.
What is the revenue of Bal Pharma Limited (BALPHARMA)?
Bal Pharma Limited reported trailing-twelve-month revenue of about ₹3.1B (latest available figure, as of Sep 27, 2026).
Does Bal Pharma Limited pay a dividend?
Bal Pharma Limited currently shows a dividend yield of about 1.11% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Bal Pharma Limited (BALPHARMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bal Pharma Limited it is ₹77.48 per share (as of Sep 27, 2026), against a price of ₹107.71. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Bal Pharma Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, BALPHARMA trades above its calculated fair value: price ₹107.71, fair value ₹77.48, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BALPHARMA?
No. The price is what the market pays today (₹107.71); the fair value is what the company's own numbers justify (₹77.48). For Bal Pharma Limited the two are ₹30.23 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bal Pharma Limited worth?
The market values Bal Pharma Limited at about ₹1.7B (market capitalisation, as of Sep 27, 2026). Per share that is ₹107.71; our models calculate a fair value of ₹77.48 per share.
What do the bullish and bearish scenarios say about BALPHARMA?
Our models span a range for Bal Pharma Limited: cautious scenario ₹40.46, base ₹77.48, optimistic ₹100.72 per share (as of Sep 27, 2026, price ₹107.71). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BALPHARMA?
Bal Pharma Limited trades at a price-to-earnings ratio of 27.3 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹77.48 is built from several models across several years. Other multiples: P/B 2.1, P/S 0.6, EV/EBITDA 6.1.
How solid is the balance sheet of Bal Pharma Limited (BALPHARMA)?
Balance-sheet figures for Bal Pharma Limited (as of Sep 27, 2026): return on equity 7.9%, debt of 0.39 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is BALPHARMA from its 52-week high?
Bal Pharma Limited trades at ₹107.71, about 6% below its 52-week high of ₹114.45 and 78% above the low of ₹60.42 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of ₹77.48 is for.
Which stocks are comparable to Bal Pharma Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bal Pharma Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹107.71, calculated fair value ₹77.48 (−28%), Quality Score 35/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BALPHARMA calculated?
We run Bal Pharma Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹77.48, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Bal Pharma Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bal Pharma Limited (BALPHARMA)?
The closing price on Sep 25, 2026 was ₹107.71. Our model-based fair value is ₹77.48, about −28% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bal Pharma Limited right now?
The price sits above even our optimistic bull case (₹100.72). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (₹40.46 to ₹100.72) leaves room in how you read the outcome.
Where does the earnings growth of Bal Pharma Limited (BALPHARMA) come from?
Earnings per share at Bal Pharma Limited grew +11.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +3.3 %, EBIT margin +4.8 %, tax rate +8.2 %, residual (interest, one-offs) −5.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bal Pharma Limited
How large is the market capitalisation of Bal Pharma Limited (BALPHARMA)?
The market capitalisation of Bal Pharma Limited is ₹1.7B (≈ $17.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bal Pharma Limited (BALPHARMA)?
The price-to-sales ratio of Bal Pharma Limited is 0.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bal Pharma Limited (BALPHARMA)?
Earnings per share at Bal Pharma Limited are ₹3.95 (price ÷ EPS = P/E 27.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bal Pharma Limited (BALPHARMA)?
The dividend yield of Bal Pharma Limited is 1.1% (payout 30.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bal Pharma Limited (BALPHARMA)?
The net margin of Bal Pharma Limited is 2.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bal Pharma Limited (BALPHARMA)?
The return on equity (ROE) of Bal Pharma Limited is 7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bal Pharma Limited (BALPHARMA)?
On an EBIT basis the return on assets of Bal Pharma Limited is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bal Pharma Limited (BALPHARMA)?
The operating margin of Bal Pharma Limited is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bal Pharma Limited (BALPHARMA)?
Revenue at Bal Pharma Limited is growing +2.7% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bal Pharma Limited (BALPHARMA)?
Earnings per share at Bal Pharma Limited are growing −33.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Bal Pharma Limited (BALPHARMA) generate?
The free cash flow of Bal Pharma Limited is −₹40.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bal Pharma Limited (BALPHARMA) carry?
The net debt of Bal Pharma Limited is ₹1.5B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bal Pharma Limited in the live analysis
One click puts Bal Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
